Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Skin Barrier Study in Chinese Pediatric AD
NCT05680298Phase 4Completed
- Sponsor
- Sanofi
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by Sanofi. Started Feb 2023; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05680298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05680298.